Neel Mahendra Butala, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aortic Valve Stenosis | 8 | 2022 | 1965 | 2.170 |
Why?
|
| Embolic Protection Devices | 3 | 2022 | 42 | 1.790 |
Why?
|
| Heart Valve Prosthesis Implantation | 5 | 2022 | 1536 | 1.000 |
Why?
|
| Directories as Topic | 1 | 2023 | 11 | 0.920 |
Why?
|
| Atherectomy, Coronary | 1 | 2023 | 148 | 0.910 |
Why?
|
| Insurance Carriers | 1 | 2023 | 157 | 0.780 |
Why?
|
| Coronary Artery Disease | 6 | 2023 | 6487 | 0.750 |
Why?
|
| Medicare | 15 | 2023 | 6566 | 0.730 |
Why?
|
| Postoperative Hemorrhage | 2 | 2021 | 413 | 0.700 |
Why?
|
| Patient Readmission | 7 | 2020 | 3114 | 0.680 |
Why?
|
| Platelet Aggregation Inhibitors | 7 | 2023 | 3068 | 0.680 |
Why?
|
| Coronary Occlusion | 1 | 2022 | 304 | 0.660 |
Why?
|
| Registries | 11 | 2022 | 8089 | 0.640 |
Why?
|
| Shock, Cardiogenic | 1 | 2023 | 688 | 0.620 |
Why?
|
| Preventive Health Services | 2 | 2013 | 575 | 0.610 |
Why?
|
| Hospitals | 5 | 2023 | 3952 | 0.610 |
Why?
|
| Economics, Hospital | 1 | 2018 | 213 | 0.540 |
Why?
|
| Treatment Outcome | 25 | 2023 | 63114 | 0.540 |
Why?
|
| Conscious Sedation | 1 | 2020 | 528 | 0.530 |
Why?
|
| Heart Valve Prosthesis | 2 | 2021 | 1488 | 0.530 |
Why?
|
| Data Mining | 1 | 2020 | 537 | 0.520 |
Why?
|
| Hospital Mortality | 6 | 2023 | 5317 | 0.490 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 397 | 0.480 |
Why?
|
| Mortality | 3 | 2018 | 2864 | 0.460 |
Why?
|
| Peripheral Arterial Disease | 2 | 2023 | 1188 | 0.460 |
Why?
|
| Data Collection | 1 | 2023 | 3341 | 0.460 |
Why?
|
| Delayed Graft Function | 1 | 2013 | 48 | 0.450 |
Why?
|
| Anesthesia, General | 1 | 2020 | 1171 | 0.440 |
Why?
|
| Mitral Valve | 2 | 2021 | 1491 | 0.420 |
Why?
|
| Diabetes Mellitus | 3 | 2015 | 5751 | 0.410 |
Why?
|
| Intensive Care Units | 2 | 2023 | 3679 | 0.400 |
Why?
|
| Seasons | 1 | 2017 | 1493 | 0.400 |
Why?
|
| Myocardial Infarction | 8 | 2021 | 11727 | 0.400 |
Why?
|
| Waiting Lists | 1 | 2015 | 692 | 0.390 |
Why?
|
| Urban Renewal | 1 | 2010 | 10 | 0.380 |
Why?
|
| Stroke | 5 | 2021 | 9981 | 0.380 |
Why?
|
| Angina Pectoris | 3 | 2022 | 977 | 0.380 |
Why?
|
| Anticoagulants | 3 | 2021 | 4599 | 0.370 |
Why?
|
| Insurance, Health | 1 | 2023 | 2494 | 0.370 |
Why?
|
| Occupational Exposure | 1 | 2020 | 1796 | 0.360 |
Why?
|
| Endovascular Procedures | 1 | 2023 | 1979 | 0.360 |
Why?
|
| United States | 25 | 2023 | 69872 | 0.360 |
Why?
|
| Sanitation | 1 | 2010 | 93 | 0.350 |
Why?
|
| Students, Medical | 2 | 2013 | 1862 | 0.350 |
Why?
|
| Stents | 2 | 2021 | 3280 | 0.350 |
Why?
|
| Kidney Transplantation | 2 | 2015 | 4251 | 0.340 |
Why?
|
| Risk Factors | 17 | 2023 | 72290 | 0.340 |
Why?
|
| Pneumonia | 2 | 2018 | 2133 | 0.330 |
Why?
|
| Water Supply | 1 | 2010 | 214 | 0.330 |
Why?
|
| Poverty Areas | 1 | 2010 | 275 | 0.330 |
Why?
|
| Community Health Centers | 1 | 2012 | 430 | 0.320 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 7913 | 0.320 |
Why?
|
| Aortic Valve | 4 | 2022 | 1922 | 0.310 |
Why?
|
| Urban Health | 1 | 2010 | 547 | 0.300 |
Why?
|
| Tissue and Organ Procurement | 1 | 2015 | 896 | 0.300 |
Why?
|
| Aged | 28 | 2023 | 163280 | 0.300 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 2759 | 0.300 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 933 | 0.300 |
Why?
|
| Health Personnel | 1 | 2020 | 3218 | 0.290 |
Why?
|
| Humans | 52 | 2023 | 744343 | 0.280 |
Why?
|
| Quality of Health Care | 3 | 2016 | 4371 | 0.280 |
Why?
|
| Tissue Donors | 1 | 2015 | 2240 | 0.280 |
Why?
|
| Coronary Angiography | 3 | 2023 | 4577 | 0.270 |
Why?
|
| Efficiency, Organizational | 1 | 2010 | 695 | 0.260 |
Why?
|
| Graft Survival | 1 | 2015 | 3737 | 0.260 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 3158 | 0.250 |
Why?
|
| Ischemic Attack, Transient | 2 | 2021 | 935 | 0.250 |
Why?
|
| Physicians | 1 | 2023 | 4567 | 0.250 |
Why?
|
| Income | 2 | 2022 | 1913 | 0.240 |
Why?
|
| Disease Management | 1 | 2015 | 2459 | 0.240 |
Why?
|
| Ambulatory Care | 1 | 2015 | 2708 | 0.230 |
Why?
|
| Communicable Disease Control | 1 | 2010 | 857 | 0.230 |
Why?
|
| Aged, 80 and over | 12 | 2022 | 57776 | 0.220 |
Why?
|
| Connecticut | 2 | 2014 | 366 | 0.220 |
Why?
|
| Quality Improvement | 2 | 2018 | 3749 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.210 |
Why?
|
| Sex Characteristics | 2 | 2014 | 2585 | 0.210 |
Why?
|
| Incidence | 6 | 2021 | 20947 | 0.200 |
Why?
|
| Hospitalization | 4 | 2020 | 10262 | 0.200 |
Why?
|
| Limb Salvage | 1 | 2023 | 433 | 0.200 |
Why?
|
| Time Factors | 8 | 2022 | 40075 | 0.190 |
Why?
|
| Nitroglycerin | 1 | 2022 | 325 | 0.190 |
Why?
|
| Risk Assessment | 3 | 2021 | 23338 | 0.190 |
Why?
|
| Glycyrrhetinic Acid | 1 | 2020 | 18 | 0.190 |
Why?
|
| Glycyrrhiza | 1 | 2020 | 11 | 0.190 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 2 | 2023 | 361 | 0.190 |
Why?
|
| Mineralocorticoids | 1 | 2020 | 38 | 0.190 |
Why?
|
| Odds Ratio | 5 | 2021 | 9849 | 0.190 |
Why?
|
| Blood Glucose | 1 | 2015 | 6256 | 0.180 |
Why?
|
| Life Expectancy | 2 | 2016 | 1184 | 0.180 |
Why?
|
| Mass Screening | 2 | 2013 | 5255 | 0.170 |
Why?
|
| Intracranial Embolism | 1 | 2021 | 202 | 0.170 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2020 | 132 | 0.170 |
Why?
|
| Propensity Score | 3 | 2021 | 1781 | 0.170 |
Why?
|
| Male | 26 | 2022 | 350118 | 0.160 |
Why?
|
| Cardiology Service, Hospital | 1 | 2020 | 246 | 0.160 |
Why?
|
| Chronic Disease | 2 | 2023 | 9146 | 0.150 |
Why?
|
| Female | 25 | 2022 | 380194 | 0.150 |
Why?
|
| Hyperaldosteronism | 1 | 2020 | 240 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2013 | 4558 | 0.150 |
Why?
|
| Middle Aged | 16 | 2023 | 213383 | 0.150 |
Why?
|
| Drug Therapy, Combination | 3 | 2023 | 6489 | 0.150 |
Why?
|
| Retrospective Studies | 8 | 2023 | 77449 | 0.140 |
Why?
|
| Heart Failure | 2 | 2018 | 10900 | 0.140 |
Why?
|
| Chest Pain | 2 | 2020 | 1114 | 0.140 |
Why?
|
| Bioprosthesis | 1 | 2020 | 596 | 0.130 |
Why?
|
| New York | 1 | 2017 | 886 | 0.130 |
Why?
|
| International Classification of Diseases | 1 | 2020 | 867 | 0.130 |
Why?
|
| Ischemia | 1 | 2023 | 1907 | 0.120 |
Why?
|
| Coronary Stenosis | 1 | 2021 | 834 | 0.120 |
Why?
|
| Patient Discharge | 4 | 2021 | 3313 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2020 | 1183 | 0.120 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 5319 | 0.110 |
Why?
|
| California | 1 | 2017 | 1402 | 0.110 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 1405 | 0.110 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 25043 | 0.110 |
Why?
|
| Cold Ischemia | 1 | 2013 | 65 | 0.110 |
Why?
|
| Health Services Research | 1 | 2020 | 1836 | 0.110 |
Why?
|
| Outpatients | 1 | 2020 | 1486 | 0.110 |
Why?
|
| Glycemic Index | 1 | 2015 | 395 | 0.110 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2020 | 1541 | 0.100 |
Why?
|
| Egypt | 1 | 2011 | 100 | 0.100 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2021 | 1422 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 1956 | 0.090 |
Why?
|
| Calcium | 1 | 2023 | 5756 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2020 | 7729 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 39050 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 1831 | 0.090 |
Why?
|
| Thrombosis | 2 | 2020 | 2968 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2021 | 15295 | 0.080 |
Why?
|
| Risk | 1 | 2020 | 9687 | 0.080 |
Why?
|
| Physical Examination | 1 | 2013 | 1237 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 7279 | 0.070 |
Why?
|
| Adult | 7 | 2023 | 214055 | 0.070 |
Why?
|
| Medicaid | 1 | 2020 | 2736 | 0.070 |
Why?
|
| Policy Making | 1 | 2010 | 554 | 0.070 |
Why?
|
| Medically Uninsured | 1 | 2012 | 853 | 0.070 |
Why?
|
| Young Adult | 5 | 2022 | 56430 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2266 | 0.070 |
Why?
|
| Disease Progression | 1 | 2022 | 13284 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 2019 | 3265 | 0.070 |
Why?
|
| Hemorrhage | 3 | 2023 | 3461 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 1671 | 0.060 |
Why?
|
| India | 1 | 2010 | 2197 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 9959 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2017 | 3336 | 0.050 |
Why?
|
| Linear Models | 1 | 2013 | 5952 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 19905 | 0.050 |
Why?
|
| Communicable Diseases | 1 | 2010 | 880 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2010 | 6459 | 0.050 |
Why?
|
| Prognosis | 1 | 2021 | 29063 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2020 | 153 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 12245 | 0.040 |
Why?
|
| Blood Chemical Analysis | 1 | 2020 | 440 | 0.040 |
Why?
|
| Aspirin | 2 | 2023 | 3282 | 0.040 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 5034 | 0.040 |
Why?
|
| Ventricular Fibrillation | 1 | 2020 | 538 | 0.040 |
Why?
|
| Health Policy | 1 | 2010 | 2661 | 0.040 |
Why?
|
| Skilled Nursing Facilities | 1 | 2021 | 372 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 15165 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2020 | 1850 | 0.030 |
Why?
|
| Aldosterone | 1 | 2020 | 877 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2022 | 1660 | 0.030 |
Why?
|
| Drug-Eluting Stents | 1 | 2021 | 753 | 0.030 |
Why?
|
| Length of Stay | 2 | 2018 | 6309 | 0.030 |
Why?
|
| Logistic Models | 2 | 2021 | 13408 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2023 | 2289 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 11725 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2020 | 2453 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2020 | 1826 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2020 | 980 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 1842 | 0.030 |
Why?
|
| Pyridones | 1 | 2016 | 712 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 3913 | 0.020 |
Why?
|
| Cause of Death | 1 | 2021 | 3584 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 1240 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2023 | 41006 | 0.020 |
Why?
|
| Warfarin | 1 | 2016 | 1496 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2016 | 2161 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2016 | 1972 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6538 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2020 | 6150 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 12959 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 10252 | 0.010 |
Why?
|
| Age Factors | 1 | 2020 | 18370 | 0.010 |
Why?
|
| Child | 2 | 2022 | 77709 | 0.010 |
Why?
|
| Adolescent | 2 | 2022 | 85781 | 0.010 |
Why?
|
| Comorbidity | 1 | 2016 | 10388 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 12354 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2020 | 25625 | 0.010 |
Why?
|
| Infant | 1 | 2020 | 35136 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20129 | 0.010 |
Why?
|